Anticarcinogenic effects of the ethanolic extract of salix aegyptiaca in colon cancer cells: Involvement of Akt/PKB and MAPK pathways

Nutrition and Cancer

Volumn 65, Issue 7, 2013, Pages 1045-1058

  Enayat, Shabnam ^a   Ceyhan, Müşerref Şeyma ^a   Başaran, Arif Ahmet ^b   Gürsel, Mayda ^a   Banerjee, Sreeparna ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID ETHYL ESTER; ANTINEOPLASTIC AGENT; APIGENIN; CATECHIN; CATECHOL; FLAVONOID; GALIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; PARA COUMARIC ACID; POLYPHENOL DERIVATIVE; PROTEIN KINASE B; QUERCETIN; RUTOSIDE; SALICIN; SALIX AEGYPTIACA EXTRACT; SALIX EXTRACT; UNCLASSIFIED DRUG; VANILLIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BARK; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; COLON CANCER; FIBROBLAST CULTURE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; OXIDATIVE STRESS; S PHASE CELL CYCLE CHECKPOINT; SALIX AEGYPTIACA; TANDEM MASS SPECTROMETRY; WILLOW;

SALIX;

ANTICARCINOGENIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FLAVONOIDS; HT29 CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASES; PLANT BARK; PLANT EXTRACTS; POLYPHENOLS; PROTO-ONCOGENE PROTEINS C-AKT; SALIX; SIGNAL TRANSDUCTION;

EID: 84888360663     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.850966     Document Type: Article

References (58)

1. Mahdi JG, Mahdi AJ, and Bowen ID: The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential. Cell Prolif 39, 147-155, 2006.
2. Chrubasik S, Kunzel O, Model A, Conradt C, and Black A: Treatment of low back pain with a herbal or synthetic anti-rheumatic: a randomized controlled study. Willow bark extract for low back pain. Rheumatology 40, 1388-1393, 2001.
3. Fiebich BL and Chrubasik S: Effects of an ethanolic Salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine 11, 135-138, 2004.
4. Hostanska K, Jurgenliemk G, Abel G, Nahrstedt A, and Saller R: Willow bark extract (BNO1455) and its fractions suppress growth and induce apoptosis in human colon and lung cancer cells. Cancer Detect and Prev 31, 129-139, 2007.
5. Karimi I, Hayatgheybi H, Shamspur T, Kamalak A, Pooyanmehr M, et al.: Chemical composition and effect of an essential oil of Salix aegyptiaca (musk willow) in hypercholesterolemic rabbit model. Rev Bras Farmacogn 21, 407-414, 2011.
6. Amin G: Popular Medicinal Plants of Iran. Tehran, Iran: Tehran University of Medical Sciences, 2005.
7. Enayat S and Banerjee S: Comparative antioxidant activity of extracts from leaves, bark and catkins of Salix aegyptiaca sp. Food Chem 116, 23-28, 2009.
8. Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, et al.: Curcumin induces the degradation of cyclin E expression through ubiquitindependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol 73, 1024-1032, 2007.
9. Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71, 1397-1421, 2006.
10. Vickers A: Recent advances: Complementary medicine. Brit Med J 321, 683-686, 2000.
11. Liu RH: Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am J Clin Nutr 78, 517S-520S, 2003.
12. Surh YJ: AGFD 89-Chemopreventive potential of some anti-inflammatory and antioxidative spice ingredients. Abstr Pap Am Chem S 234, 89-AGFD, 2007.
13. Wang MY, Dhingra K, Hittelman WN, Liehr JG, deAndradeM, et al.: Lipid peroxidation-induced putative malondialdehyde-DNA adducts in human breast tissues. Cancer Epidem Biomar 5, 705-710, 1996.
14. Terzic J, Grivennikov S, Karin E, and Karin M: Inflammation and colon cancer. Gastroenterology 138, 2101-2114, 2010.
15. N'Guessan JD, Bidie AP, Lenta BN,Weniger B, Andre P, et al.: In vitro assays for bioactivity-guided isolation of antisalmonella and antioxidant compounds in Thonningia sanguinea flowers. Afr J Biotechnol 6, 1685-1689, 2007.
16. Gezer K, Duru ME, Kivrak I, et al.: Free-radical scavenging capacity and antimicrobial activity of wild edible mushroom from Turkey. Afr J Biotechnol 5, 1924-1928, 2006.
17. Kim DO, Jeong SW, and Lee CY: Antioxidant capacity of phenolic phytochemicals from various cultivars of plums. Food Chem 81, 321-326, 2003.
18. Paul M, Bruning G, Weihrather J, and Jauch J: Qualitative and quantitative analysis of 17 different types of tetra-and pentacyclic triterpenic acids in boswellia papyrifera by a semi-automatic homomodal 2D HPLC method. Chromatographia 74, 29-40, 2011.
19. Reif K, Burgering BMT, and Cantrell DA: Phosphatidylinositol 3-kinase links the interleukin-2 receptor to protein kinase B and p70 S6 kinase. J Biol Chem 272, 14426-14433, 1997.
20. Cimen I, Tuncay S, and Banerjee S: 15-Lipoxygenase-1 expression suppresses the invasive properties of colorectal carcinoma cell lines HCT-116 and HT-29. Cancer Sci 100, 2283-2291, 2009.
21. Szczepanski MA, Grzanka A, Litwiniec A, Gackowska L, Kubiszewska I, et al.: The assessment of A549 lung cancer cells response to cisplatin considering cytoskeletal organization. Cytom Part B-Clin Cy 76B, 431-432, 2009.
22. Nomura Y, Bhawal UK, Nishikiori R, Sawajiri M, Maeda T, et al.: Effects of high-dose major components in oral disinfectants on the cell cycle and apoptosis in primary human gingival fibroblasts in vitro. Dent Mater J 29, 75-83, 2010.
23. Rook GAW, Steele J, Umar S, and Dockrell HM: A Simple method for the solubilization of reduced Nbt, and its use as a colorimetric assay for activation of human macrophages by gamma-interferon. J Immunol Methods 82, 161-167, 1985.
24. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, et al.: Role of p53 and NF-kappa B in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 22, 4851-4859, 2003.
25. Hastak K, Agarwal MK, Mukhtar H, and Agarwal ML: Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. Faseb J 19, 789-791, 2005.
26. da FrotaML, Jr., Braganhol E, Canedo AD, et al.: Extracts of marine sponge Polymastia janeirensis induce oxidative cell death through a caspase-9 apoptotic pathway in human U138MG glioma cell line. Invest New Drugs 27, 440-446, 2009.
27. Rao SD and Pagidas K: Epigallocatechin-3-gallate, a natural polyphenol, inhibits cell proliferation and induces apoptosis in human ovarian cancer cells. Anticancer Res 30, 2519-2523, 2010.
28. Niida H, Murata K, Shimada M, Ogawa K, Ohta K, et al.: Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo. Embo J 29, 3558-3570, 2010.
29. Chen WS, Lee YJ, Yu YC, Hsaio CH, Yen JH, et al.: Enhancement Of P53-mutant human colorectal cancer cells radiosensitivity by flavonoid fisetin. Int J Radiat Oncol 77, 1527-1535, 2010.
30. Mayo LD and Donner DB: A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. P Natl Acad Sci USA 98, 11598-11603, 2001.
31. Nalla AK, Estes N, Patel J, and Rao JS: N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K/Akt signaling in prostate cancer cells. Exp Cell Res 317, 2512-2521, 2011.
32. Lee YR, Park J, Yu HN, Kim JS, Youn HJ, et al.: Up-regulation of PI3K/Akt signaling by 17 beta-estradiol through activation of estrogen receptor-alpha but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells. Biochem Biophy Res Co 336, 1221-1226, 2005.
33. PanMH, Lin CC, Lin JK, andChenWJ: Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta 1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling. J Agr Food Chem 55, 5030-5037, 2007.
34. Mendoza MC, Er EE, and Blenis J: The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36, 320-328, 2011.
35. Lee KW, Bode AM, and Dong Z: Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer 11, 211-218, 2011.
36. Manthey JA and Guthrie N: Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J Agric Food Chem 50, 5837-5843, 2002.
37. Vlachojannis J, Magora F, and Chrubasik S: Willow species and aspirin: different mechanism of actions. Phytother Res 25, 1102-1104, 2011.
38. Yang J, Liu RH, and Halim L: Antioxidant and antiproliferative activities of common edible nut seeds. Lwt-Food SciTechnol 42, 1-8, 2009.
39. Hostanska K, Jurgenliemk G, Nahrstedt A, Abel G, and Saller R: Willow bark extract (BNO 1455) and its fraction of salicyl alcohol derivates promote apoptosis in human colon cancer cell lines irrespective their cyclooxygenase-2 status. Ann Oncol 18, vii38-vii38, 2007.
40. Watson JL, Hill R, Yaffe PB, Greenshields A, Walsh M, et al.: Curcumin causes superoxide anion production and p53-independent apoptosis in human colon cancer cells. Cancer Lett 297, 1-8, 2010.
41. Zhou BHP, Liao Y, XiaWY, Zou YY, Spohn B, et al.: HER-2/neu induces p53 ubiquitination via Akt-mediatedMDM2phosphorylation. Nat Cell Biol 3, 973-982, 2001.
42. Pochampally R, Fodera B, Chen LH, Shao WJ, Levine EA, et al.: A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Oncogene 17, 2629-2636, 1998.
43. Cheng TH and Cohen SN: HumanMDM2 isoforms translated differentially on constitutive versus p53-regulated transcripts have distinct functions in the p53/MDM2 and TSG101/MDM2 feedback control loops. Mol Cell Biol 27, 111-119, 2007.
44. Gruson D, Ginion A, Decroly N, Lause P, Vanoverschelde JL, et al.: Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3 beta signaling pathway. Peptides 31, 1326-1333, 2010.
45. Liu JC, Chen CH, Chen JJ, and Cheng TH: Urotensin II Induces rat cardiomyocyte hypertrophy via the transient oxidization of Src homology 2-containing tyrosine phosphatase and transactivation of epidermal growth factor receptor. Mol Pharmacol 76, 1186-1195, 2009.
46. Onan D, Pipolo L, Yang E, Hannan RD, and Thomas WG: Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 18, 2344-2354, 2004.
47. Downward J: Targeting ras signalling pathways in cancer therapy. Nat Rev Cancer 3, 11-22, 2003.
48. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, et al.: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813-822, 1999.
49. Lin AN and Dibling B: The true face of JNK activation in apoptosis. Aging Cell 1, 112-116, 2002.
50. Liu J and Lin AN: Role of JNK activation in apoptosis: A double-edged sword. Cell Res 15, 36-42, 2005.
51. Hibi M, Lin AN, Smeal T, Minden A, and Karin M: Identification of an oncoprotein-responsive and UV-responsive protein-kinase that binds and potentiates the c-jun activation domain. Gene Dev 7, 2135-2148, 1993.
52. Uehara T, Bennett B, Sakata ST, Satoh Y, Bilter GK, et al.: JNK mediates hepatic ischemia reperfusion injury. J Hepatol 42, 850-859, 2005.
53. Cano E, Hazzalin CA, and Mahadevan LC: Anisomycin-activated protein kinase-P45 and kinase-P55 but not mitogen-activated protein kinase-Erk-1 And kinase-Erk-2 Are implicated in the induction of c-fos and c-jun. Mol Cell Biol 14, 7352-7362, 1994.
54. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, et al.: p38 alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 11, 191-205, 2007.
55. deLaat A, vanderLeun JC, and deGruijl FR: Carcinogenesis induced by UVA (365-nm) radiation: The dose-time dependence of tumor formation in hairless mice. Carcinogenesis 18, 1013-1020, 1997.
56. Gupta S, Kass GEN, Szegezdi E, and Joseph B: The mitochondrial death pathway: a promising therapeutic target in diseases. J Cell Mol Med 13, 1004-1033, 2009.
57. Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, and Hainaut P: Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther 18, 2-11, 2011.
58. Wiman KG: Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 29, 4245-4252, 2010.